Evidence map›Paper›PMID 40903459›Full record

ArticleTranslational psychiatry2025

Nesfatin-1 ameliorates blood-brain barrier dysfunction in Alzheimer's disease by targeting VEGF-R1 and reducing cellular senescence in brain vascular endothelial cells.

Biyue Zhang, Shumei Zhang, Zeming Guo, Chunzhan Hong, Futian Zhang, Huasong Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Biyue Zhang *Department of Neurology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, China.
Shumei Zhang *Department of Implant Dentistry III, Stomatological Hospital of Xiamen Medical College, Xiamen, Fujian, 361006, China.
Zeming Guo *Department of Neurology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, China.
Chunzhan HongDepartment of Neurology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, China.
Futian ZhangDepartment of Neurology, Nan'an Hospital, Quanzhou, Fujian, 362300, China. hhuxwc758nf95@163.com.
Huasong LinDepartment of Geriatric Medicine, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518107, China. hslin3855@126.com.ORCID http://orcid.org/0009-0009-1222-3168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular senescence and associated endothelial permeability are crucial factors in the dysfunction of the blood-brain barrier (BBB) in neurodegenerative diseases, including Alzheimer's disease (AD). Nesfatin-1 (NF-1), a neuropeptide involved in regulating appetite and energy homeostasis, has not been extensively studied for its pathophysiological role in AD. In this study, we found that NF-1 treatment improved cellular senescence in brain vascular endothelial bEnd.3 cells by restoring the expression of hTERT and TERF2 against oligomerized Aβ

Indexed as

Alzheimer DiseaseBlood-Brain BarrierCellular SenescenceEndothelial CellsNucleobindinsAmyloid beta-PeptidesAnimalsBrainDisease Models, AnimalHumansMaleMiceMice, TransgenicPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)NucleobindinsPeptide Fragments

Identifiers

PMID40903459
PMCPMC12408809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.